Peyronie's disease: Evaluation and review of nonsurgical therapy

TheScientificWorldJournal

Volumn 9, Issue , 2009, Pages 665-675

  Abern, Michael R ^a   Levine, Laurence A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Penile induration; Peyronie's disease

Indexed keywords

4 AMINOBENZOATE POTASSIUM; ALPHA TOCOPHEROL; ALPHA2B INTERFERON; ARGININE; CARNITINE; COLCHICINE; COLLAGENASE; CORTISONE; DEXAMETHASONE; HYDROCORTISONE; INTERFERON; LEVACECARNINE; PENTOXIFYLLINE; TAMOXIFEN CITRATE; TRIAMCINOLONE; VERAPAMIL;

ALOPECIA; APLASTIC ANEMIA; ATROPHY; CLINICAL TRIAL; DERMATOMYOSITIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; EXTRACORPOREAL LITHOTRIPSY; FEVER; FIBROSIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNE DEFICIENCY; IONTOPHORESIS; MEDLINE; MYALGIA; PATIENT MONITORING; PEMPHIGUS; PENIS DISEASE; PEYRONIE DISEASE; PHYSICAL EXAMINATION; QUESTIONNAIRE; REVIEW; SCLERODERMA; TISSUE ATROPHY; TRACTION THERAPY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VACUUM; VALIDATION PROCESS; MALE; MONITORING;

HUMANS; MALE; MONITORING, PHYSIOLOGIC; PENILE INDURATION;

EID: 70350761933     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2009.92     Document Type: Review

References (69)

1. La Peyronie, F. (1743) Sur quelques obstaclesqui sópposent à ĺjaculation nautrelle de la semence. Mem. Acad. R. Chir. 1, 337-342.
2. Levine, L.A. and Greenfield, J.M. (2003) Establishing a standardized evaluation of the man with Peyronie's disease. Int. J. Impot. Res. 15(Suppl. 5), S103-112.
3. Bleustein, C.B., Eckholdt, H., Arezzo, J.C., and Melman, A. (2003) Quantitative somatosensory testing of the penis: optimizing the clinical neurological examination. J. Urol. 169(6), 2266-2269. (Pubitemid 36576768)
4. Deveci, S., Hopps, C.V., O'Brien, K., et al. (2007) Defining the clinical characteristics of Peyronie's disease in young men. J. Sex. Med. 4(2), 485-490. (Pubitemid 46394722)
5. Williams, J.L. and Thomas, G.G. (1970) The natural history of Peyronie's disease. J. Urol. 103, 75.
6. Gelbard, M.K., Dorey, F., and James, K. (1990) The natural history of Peyronie's disease. J. Urol. 144, 1376-1379.
7. Kadioglu, A. et al. (2002) A retrospective review of 307 men with Peyronie's disease. J. Urol. 168, 1075-1079. (Pubitemid 34898332)
8. Scott, W.W. and Scardino, P.L. (1948) A new concept in the treatment of Peyronie's disease. South. Med. J. 41, 173-177.
9. Sikka, S.C. and Hellstrom, W.J. (2002) Role of oxidative stress and antioxidants in Peyronie's disease. Int. J. Impot. Res. 14, 353-360. (Pubitemid 35285285)
10. Gholami, S.S., Gonzalez-Cadavid, N.F., Lue, T.F., et al. (2002) Peyronie's disease: a review. J. Urol. 169, 1234-1241.
11. Pryor, J.P. and Farrell, C.F. (1983) Controlled clinical trial of vitamin E in Peyronie's disease. Prog. Reprod. Biol. 9, 41-45.
12. Safarinejad, M.R., Hosseini, S.Y., and Kolahi, A.A. (2007) Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. J. Urol. 178, 1398-1403.
13. www.mdconsult.com
14. Akkus, E., Carrier, S., Rehman, J., et al. (1994) Is colchicine effective in Peyronie's disease? A pilot study. Urology 44, 291-295. (Pubitemid 24246173)
15. Kadioglu, A., Tefekli, A., Koksal, T., et al. (2000) Treatment of Peyronie's disease with oral colchicine: long term results and predictive parameters of successful outcome. Int. J. Impot. Res. 12, 169-175.
16. Safarinejad, M.R. (2004) Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study. Int. J. Impot. Res. 16, 238-243.
17. Zarafonetis, C.J. and Horrax, T.M. (1959) Treatment of Peyronie's disease with potassium para-aminobenzoate (potaba). J. Urol. 81, 770-772.
18. Hasche-Klunder, R. (1978) Treatment of peyronie's disease with para-aminobenzoacidic potassium (POTABA) (author's transl.) Urologe A 17, 224-227.
19. Weidner, W., Schroeder-Printzen, I., Rudnick, J., et al. (1999) Randomized prospective placebo-controlled therapy of Peyronie's disease (IPP) with Potaba (aminobenzoate potassium). J. Urol. 6, 205.
20. Weidner, W., Hauck, E.W., and Schnitker, J. (2005) Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur. Urol. 47, 530-535. (Pubitemid 40357904)
21. Ralph, D.J., Brooks, M.D., Bottazzo, G.F., et al. (1992) The treatment of Peyronie's disease with tamoxifen. Br. J. Urol. 70, 648-651.
22. Colletta, A.A., Wakefield, L.M., Howell, F.V., et al. (1990) Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br. J. Cancer 62, 405-409. (Pubitemid 20292836)
23. Teloken, C., Rhoden, E.L., Grazziotin, T.M., et al. (1999) Tamoxifen versus placebo in the treatment of Peyronie's disease. J. Urol. 162, 2003-2005.
24. Biagiotti, G. and Cavallini, G. (2001) Acetyl-L-carnitine vs. tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int. 88, 63-67. (Pubitemid 33755042)
25. Valente, E.G., Vernet, D., Ferrini, M., et al. (2003) L-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 9, 229-244. (Pubitemid 38294362)
26. Brant, W.O., Dean, R.C., and Lue, T.F. (2006) Treatment of Peyronie's disease with oral pentoxifylline. Nat. Clin. Pract. Urol. 3, 111-115. (Pubitemid 43239268)
27. Martin, D.J., Badwan, K., Parker, M., et al. (2002) Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J. Urol. 168, 2483-2485. (Pubitemid 35402645)
28. Fitch, W.P., Easterling, J., Talbert, R.L., et al. (2007) Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease - a placebo-controlled pilot study. J. Sex. Med. 4, 477-484. (Pubitemid 46394721)
29. Levine, L.A. (2007) Comment on topical verpamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease - a placebo-controlled pilot study. J. Sex. Med. 4, 1081-1082. (Pubitemid 47079643)
30. Bodner, H., Howard, A.H., and Kaplan, J.H. (1954) Peyronie's disease: cortisone-hyaluronidase-hydrocortisone therapy. J. Urol. 72(3), 400-403.
31. Winter, C.C. and Khanna, R. (1975) Peyronie's disease: results with dermo-jet injection of dexamethasone. J. Urol. 114, 898-900.
32. Williams, G. and Green, N.A. (1980) The non-surgical treatment of Peyronie's disease. Br. J. Urol. 52, 392-395.
33. Gelbard, M.K., Walsh, R., and Kaufman, J.J. (1982) Collagenase for Peyronie's disease experimental studies. Urol. Res. 10, 135-140. (Pubitemid 12046996)
34. Gelbard, M.K., Linkner, A., and Kaufman, J.J. (1985) The use of collagenase in the treatment of Peyronie's disease J. Urol. 134, 280-283. (Pubitemid 15006547)
35. Gelbard, M.K., James, K., Riach, P., and Dorey, F. (1993) Collagenase vs. placebo in the treatment of Peyronie's disease: a double blind study. J. Urol. 149, 56-58. (Pubitemid 23095473)
36. Roth, M., Eickelberg, O., Kohler, E., et al. (1996) Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc. Natl. Acad. Sci. U. S. A. 93, 5478-5482. (Pubitemid 26159475)
37. Mulhall, J.P., Anderson, M.S., Lubrano, T., et al. (2002) Peyronie's disease cell culture models: phenotypic, genotypic and functional analyses. Int. J. Impot. Res. 14, 397-405. (Pubitemid 35285291)
38. Levine, L.A., Merrick, P.F., and Lee, R.C. (1994) Intralesional verapamil injection for the treatment of Peyronie's disease. J. Urol. 151, 1522-1524.
39. Rehman, J., Benet, A., and Melman, A. (1998) Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long term single-blind study. Urology 51, 620-626. (Pubitemid 28186217)
40. Levine, L.A. and Estrada, C.R. (2002) Intralesional verapamil for the treatment of Peyronie's disease: a review. Int. J. Impot. Res. 14, 324-328. (Pubitemid 35285280)
41. Bennett, N.E., Guhring, P., and Mulhall, J.P. (2007) Intralesional verapamil prevents the progression of Peyronie's disease. Urology 69, 1181-1184. (Pubitemid 46891587)
42. Duncan, M.R., Berman, B., and Nseyo, U.O. (1991) Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-α, β and γ. Scand. J. Urol. Nephrol. 25, 89-94.
43. Wegner, H.E., Andreson, R., Knipsel, H.H., et al. (1995) Treatment of Peyronie's disease with local interferon-α-2b. Eur. Urol. 28, 236-240.
44. Wegner, H.E., Andresen, R., Knipsel, H.H., et al. (1997) Local interferon-α-2b is not an effective treatment in earlystage Peyronie's disease. Eur. Urol. 32, 190-193. (Pubitemid 27386960)
45. Ahuja, S., Bivalacqua, T.J., Case, J., Vincent, M., Sikka, S.C., and Hellstrom, W.J. (1999) A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie's disease. J. Androl. 20, 444-448. (Pubitemid 29362624)
46. Dang, G., Matern, R., Bivalacqua, T.J., et al. (2004) Intralesional interferon-α-2b injections for the treatment of Peyronie's disease. South. Med. J. 97, 42-46. (Pubitemid 38112474)
47. Hellstrom, W.J., Kendirici, M., Matern, R., et al. (2006) Single-blind, multicenter placebo-controlled parallel study to asses the safety and efficacy of intralesional interferon-α-2b for minimally invasive treatment for Peyronie's disease. J. Urol. 176, 394-398. (Pubitemid 43833173)
48. Levine, L.A. (2003) Review of current nonsurgical management of Peyronie's disease. Int. J. Impot. Res. 15, S113-120.
49. Hauck, E.W., Altinkilic, B.M., Ludwig, M., et al. (2000) Extracorporeal shock wave therapy in the treatment of Peyronie's disease. First results of a case-controlled approach. Eur. Urol. 38, 663-669.
50. Hatzichristodoulou, G., Meisner, C., et al. (2006) Efficacy of Extracorporeal Shock Wave Therapy (ESWT) in Patients with Peyronie's Disease (PD) - First Results of a Prospective, Randomized, Placebo-Controlled, Single-Blind Study. Abstr. 993. Annual Meeting of the American Urological Association. May 20-25. Atlanta, GA.
51. Hatzichristodoulou, G., Meisner, C., et al. (2007) Efficacy of Extracorporeal Shock Wave Therapy on Plaque Size and Sexual Function in Patients with Peyronie's Disease - Results of a Prospective, Randomized, Placebo-Controlled Study. Abstr. 747. Annual Meeting of the American Urological Association. May 19-24. Anaheim, CA.
52. Riedl, C.R., Plas, E., Engelhard, P., et al. (2000) Iontophoresis for treatment of Peyronie's disease. J. Urol. 163, 95-99.
53. Montorsi, F., Salonia, A., Guazzoni, G., et al. (2000) Transdermal electromotive multi-drug administration for Peyronie's disease: preliminary results. J. Androl. 21, 85-90. (Pubitemid 30069085)
54. Di Stasi, S.M., Giannantoni, A., Capelli, G., et al. (2003) Transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. BJU Int. 91, 825-829. (Pubitemid 36724069)
55. Di Stasi, S.M., Giannantoni, A., Stephen, R.L., et al. (2004) A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J. Urol. 171, 1605-1608. (Pubitemid 38365431)
56. Levine, L.A., Estrada, C.R., Shou, W., et al. (2003) Tunica albuginea tissue analysis after electromotive drug administration. J. Urol. 169, 1775-1778. (Pubitemid 36443494)
57. Greenfield, J.M., Shah, S.J., and Levine, L.A. (2007) Verapamil vs. saline in electromotive drug administration (EDMA) for Peyronie's disease: a double blind, placebo controlled trial. J. Urol. 177, 972-975.
58. Ojingwa, J.C. and Isseroff, R.R. (2003) Electrical stimulation of wound healing. J. Invest. Dermatol. 121, 1-12.
59. Abern, M. and Levine, L. (2007) Intralesional Verapamil Injections with and without Vacuum Therapy for Management of Peyronie's Disease. Abstracts from the Sexual Medicine Society of North America Fall Meeting. December 5-9. Chicago.
60. Alenghat, F.J. and Ingber, D.E. (2002) Mechanotransduction: all signals point to cytoskeleton, matrix, and integrins. Sci STKE 2002(119), PE6.
61. Alman, B.A., Naber, S.P., Terek, R.M., Jiranek, W.A., Goldberg, M.J., and Wolfe, H.J. (1995) Platelet-derived growth factor in fibrous musculoskeletal disorders: a study of pathologic tissue sections and in vitro primary cell cultures. J. Orthop. Res. 13(1), 67-77.
62. Brighton, C.T., Fisher, J.R., Jr., Levine, S.E., Corsetti, J.R., Reilly, T., Landsman, A.S., Williams, J.L., and Thibault, L.E. (1996) The biochemical pathway mediating the proliferative response of bone cells to a mechanical stimulus. J. Bone Joint Surg. Am. 78(9), 1337-1347. (Pubitemid 26336884)
63. Levine, L.A., Newell, M., and Taylor, F.L. (2008) Penile traction therapy for treatment of Peyronie's disease: a single-center pilot study. J. Sex. Med. 5(6), 1468-1473. (Pubitemid 351803113)
64. Preito Castro, R.M., Leva Vallejo, M.E., Regueiro Lopez, J.C., et al. (2003) Combined treatment with vitamin E and colchicines in the early stages of Peyronie's disease. BJU Int. 91, 522-524. (Pubitemid 36570574)
65. Mirone, V., Imbimbo, C., Palmieri, A., et al. (1999) Our experience on the association of a new physical and medical therapy in patients suffering from induration penis plastica. Eur. Urol. 36, 327-330. (Pubitemid 29419450)
66. Mirone, V., Palmieri, A., Granata, A.M., et al. (2000) Ultrasound-guided ESWT in Peyronie's disease plaques. Arch. Ital. Urol. Androl. 72, 384-387. (Pubitemid 32125570)
67. Cavallini, G., Biagiotti, G., Koverech, A., et al. (2002) Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU Int. 89, 895-900. (Pubitemid 34535423)
68. Abern, M. and Levine, L. (2008) Intralesional Verapamil Injections with and without Penile Traction and Oral Therapies for Management of Peyronie's Disease. Abstracts from the Sexual Medicine Society of North America Fall Meeting. October 16-19. Toronto, Ontario.
69. Jordan, G.H. (2008) The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study. J. Sex. Med. 5(1), 180-187.